Jie Dai1, Ming Liu1, Stephen J Swensen2, Shawn M Stoddard3, Jason A Wampfler4, Andrew H Limper5, Gening Jiang6, Ping Yang7. 1. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 2. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 3. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 5. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. 6. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. 7. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address: yang.ping@mayo.edu.
Abstract
INTRODUCTION: Pulmonary emphysema is a frequent comorbidity in lung cancer, but its role in tumor prognosis remains obscure. Our aim was to evaluate the impact of the regional emphysema score (RES) on a patient's overall survival, quality of life (QOL), and recovery of pulmonary function in stage I to II lung cancer. METHODS: Between 1997 and 2009, a total of 1073 patients were identified and divided into two surgical groups-cancer in the emphysematous (group 1 [n = 565]) and nonemphysematous (group 2 [n = 435]) regions-and one nonsurgical group (group 3 [n = 73]). RES was derived from the emphysematous region and categorized as mild (≤5%), moderate (6%-24%), or severe (25%-60%). RESULTS: In group 1, patients with a moderate or severe RES experienced slight decreases in postoperative forced expiratory volume in 1 second, but increases in the ratio of forced expiratory volume in 1 second to forced vital capacity compared with those with a mild RES (p < 0.01); however, this correlation was not observed in group 2. Posttreatment QOL was lower in patients with higher RESs in all groups, mainly owing to dyspnea (p < 0.05). Cox regression analysis revealed that patients with a higher RES had significantly poorer survival in both surgical groups, with adjusted hazard ratios of 1.41 and 1.43 for a moderate RES and 1.63 and 2.04 for a severe RES, respectively; however, this association was insignificant in the nonsurgical group (adjusted hazard ratio of 0.99 for a moderate or severe RES). CONCLUSIONS: In surgically treated patients with cancer in the emphysematous region, RES is associated with postoperative changes in lung function. RES is also predictive of posttreatment QOL related to dyspnea in early-stage lung cancer. In both surgical groups, RES is an independent predictor of survival.
INTRODUCTION:Pulmonary emphysema is a frequent comorbidity in lung cancer, but its role in tumor prognosis remains obscure. Our aim was to evaluate the impact of the regional emphysema score (RES) on a patient's overall survival, quality of life (QOL), and recovery of pulmonary function in stage I to II lung cancer. METHODS: Between 1997 and 2009, a total of 1073 patients were identified and divided into two surgical groups-cancer in the emphysematous (group 1 [n = 565]) and nonemphysematous (group 2 [n = 435]) regions-and one nonsurgical group (group 3 [n = 73]). RES was derived from the emphysematous region and categorized as mild (≤5%), moderate (6%-24%), or severe (25%-60%). RESULTS: In group 1, patients with a moderate or severe RES experienced slight decreases in postoperative forced expiratory volume in 1 second, but increases in the ratio of forced expiratory volume in 1 second to forced vital capacity compared with those with a mild RES (p < 0.01); however, this correlation was not observed in group 2. Posttreatment QOL was lower in patients with higher RESs in all groups, mainly owing to dyspnea (p < 0.05). Cox regression analysis revealed that patients with a higher RES had significantly poorer survival in both surgical groups, with adjusted hazard ratios of 1.41 and 1.43 for a moderate RES and 1.63 and 2.04 for a severe RES, respectively; however, this association was insignificant in the nonsurgical group (adjusted hazard ratio of 0.99 for a moderate or severe RES). CONCLUSIONS: In surgically treated patients with cancer in the emphysematous region, RES is associated with postoperative changes in lung function. RES is also predictive of posttreatment QOL related to dyspnea in early-stage lung cancer. In both surgical groups, RES is an independent predictor of survival.
Authors: Pablo Sanchez-Salcedo; David O Wilson; Juan P de-Torres; Joel L Weissfeld; Juan Berto; Arantzazu Campo; Ana B Alcaide; Jesús Pueyo; Gorka Bastarrika; Luis M Seijo; Maria J Pajares; Ruben Pio; Luis M Montuenga; Javier J Zulueta Journal: Am J Respir Crit Care Med Date: 2015-04-15 Impact factor: 21.405
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta Journal: Chest Date: 2007-12 Impact factor: 9.410
Authors: Laurie A Hohberger; Darrell R Schroeder; Brian J Bartholmai; Ping Yang; Christine H Wendt; Peter B Bitterman; Ola Larsson; Andrew H Limper Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Elizabeth C Oelsner; J Jeffrey Carr; Paul L Enright; Eric A Hoffman; Aaron R Folsom; Steven M Kawut; Richard A Kronmal; David J Lederer; Joao A C Lima; Gina S Lovasi; Benjamin M Smith; Steven J Shea; R Graham Barr Journal: Thorax Date: 2016-04-05 Impact factor: 9.139
Authors: Jie Dai; Yanqi He; Kunlatida Maneenil; Han Liu; Ming Liu; Qian Guo; Amy C Bennett; Shawn M Stoddard; Jason A Wampfler; Gening Jiang; Ping Yang Journal: Transl Lung Cancer Res Date: 2021-03